Navigation Links
Kronos Announces First Quarter Business Update and Financial Results
Date:11/15/2007

ement with EOL, Kronos' medical partner for manufacturing and distributing Kronos air purifiers in Russia and other Commonwealth of Independent States.

In addition, EOL provided further independent technology testing and validation of the Kronos technology. The Russian National Healthcare Institution Vladimir Regional Tuberculosis Prevention and Treatment Center conducted in-patient room testing to assess the effectiveness of Kronos-based air purifiers for use in disinfecting rooms used to treat TB patients. Dr. Volchenkov, Chief Physician for the Regional Tuberculosis Prevention and Treatment Center concluded the Kronos-based air purifier demonstrated "a high reliable decrease in the microorganisms in the room." Dr. Volchenkov further stated that the Kronos-based "device can be used for air cleaning and disinfection in the rooms of tuberculosis prevention and treatment centers having high infection rates."

Intellectual Property.

During the quarter, Kronos obtained two additional foreign patents. This brings Kronos' total patent portfolio to thirteen U.S. patents and five international patents with additional patents pending.

Financial Results

Kronos recorded a net loss for each of the quarters ended September 30, 2007 and September 30, 2006 of $1,463,000 and $843,000, respectively. The increase in the net loss in the quarter ended September 30, 2007 was principally the result of a $301,000 increase in operating costs to $1,054,000, and a $335,000 increase in interest expense to $435,000.

Revenues for the quarter ended September 30, 2007 were $25,000 compared to $19,000 for the comparable period of 2006. Revenues for the quarter ended September 30, 2007 consisted of fees from our license agreement with EOL. Selling, General and Administrative expenses for the quarter ended September 30, 2007 increased $301,000 from the corresponding period of 2006 to $1,054,000. The increase was principally the result of a $207,000 increase in com
'/>"/>

SOURCE Kronos Advanced Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Novartis, ranibizumab was approved by CFDA ... 2012. Currently, only Lucentis, a product of Novartis, is ... as the first self- developed drug for the treatment ...
(Date:8/28/2015)...  IP Shakti, LLC, today announced that it has changed ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... identity signifies our transformation into a company focused on patent ... patent claim validity." ... Shield™ platform, the Company commenced a corporate re-branding initiative in ...
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... OMER ) today announced that it has obtained ... California to a new series of antifibrinolytic agents. These optimized ... surgical and traumatic bleeding. "This is a ... for patients. With the withdrawal of Trasylol® from the market ...
... Jan. 5, 2011 Karyopharm Therapeutics Inc., a pioneer ... modulators, announces the recruitment of a highly experienced cancer ... Chief Executive Officer. Dr. Kauffman will join Sharon Shacham, ... and Development, as its executive management team. Kauffman,s appointment ...
Cached Medicine Technology:Omeros Licenses Novel Antifibrinolytic Agents 2Omeros Licenses Novel Antifibrinolytic Agents 3Omeros Licenses Novel Antifibrinolytic Agents 4Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer 2Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer 3
(Date:8/30/2015)... ... ... Lizzie’s Lice Pickers , a company that offers professional live removal ... lice head checks for just $10, which is a significant discount from the normal ... lice treatment products. “With kids returning to school, it is very important to be ...
(Date:8/30/2015)... Fl (PRWEB) , ... August 30, 2015 , ... ... Executive Vice President Jeff Fernandez will lead the expansion of global cosmeceutical and ... and skin care experience having spent the last 25 years working in operations, ...
(Date:8/29/2015)... ... August 30, 2015 , ... ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The ... simple digital handwritten signature. , Clinical trial sites can now use ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and ... is to increase acceptance of the chiropractic field in the military. All too often ... Although Chiropractic was made available to the VA program over a decade ago, ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 ... ... successful results and include treating the localized area with stretching, soft tissue manipulation. ... a neutral pelvic position have shown through research to improve treatment outcomes. ...
Breaking Medicine News(10 mins):Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... be removed ahead of time, FDA says, , , THURSDAY, ... Drug Administration warned Thursday that some medication skin patches ... MRI. , Thursday,s warning applies to brand name and ... and pain-control patches. , Some of these patches do ...
... How messages sent within stem cells through a specific communication ... cells in humans, has been discovered by scientists of the ... to be published in the March 6 issue of ... demonstrated the importance of the pathway, known as the noncanonical ...
... New Rochelle, NY, March 5, 2009Serious flaws in a ... C reduce the effectiveness of chemotherapeutic drugs in the ... of Alternative and Complementary Therapies , a journal ... This report is available free online at ...
... potential risk from exposure to medications, chemicals and other ... risks of taking cold medication or using certain cleaning ... the phone. A new Web site ( ... finding the latest information about the potential risks of ...
... therapies to restore sight, experts suggest , , THURSDAY, March ... major role in two forms of childhood blindness has ... The discovery of the link between the retinal gene ... is important because it pinpoints a new retinal metabolic ...
... top 100 property and casualty insurers closed 2008 with ... years, while the top 100 life insurers suffered unprecedented ... Data 2008 Top 100 Performance Monitor revealed a 67.7 ... the industry,s top property and casualty insurers, from $48.8 ...
Cached Medicine News:Health News:Skin Patches Can Cause Burns During MRIs 2Health News:Support for adjunctive vitamin C treatment in cancer 2Health News:New Online Service Helps Expectant Moms 2Health News:Retinal Gene Is Linked to Childhood Blindness 2Health News:Highline Data Analysis Shows Year-over-Year P&C Industry Net Income Down 67.7%, Life Industry Net Unrealized Capital Losses Totaled $51.7 billion in 2008 2Health News:Highline Data Analysis Shows Year-over-Year P&C Industry Net Income Down 67.7%, Life Industry Net Unrealized Capital Losses Totaled $51.7 billion in 2008 3
... parafollicular C-cells of the thyroid gland and ... action of calcitonin is to lower plasma ... in decreased mobilization of calcium from bone ... conditions associated with high levels of bone ...
Calcitonin RIA Kit...
... The Matrix Perimeter utilizes Welch ... a significant breakthrough in visual field ... capabilities, tools to characterize glaucoma and ... Humphrey FDT Perimeter, the Matrix doubles ...
... digital camera system by KARL STORZ, a ... camera systems. Digital Source Sampling technology, applied ... fully digital transfer of information with no ... as well as loss-free data storage on ...
Medicine Products: